A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Elenbecestat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 14 Apr 2017 Status changed from recruiting to completed.
- 07 Mar 2017 New trial record
- 24 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Apr 2017.